Evidence mapPaperPMID 39471413Full record

ArticleBriefings in bioinformatics2024

A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors.

Zachary D Wallen, Mary K Nesline, Sarabjot Pabla, Shuang Gao, Erik Vanroey, Stephanie B Hastings, Heidi Ko, Kyle C Strickland, Rebecca A Previs, Shengle Zhang and 8 more

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zachary D WallenMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.ORCID 0000-0002-2278-7348
Mary K NeslineMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Sarabjot PablaMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Shuang GaoMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Erik VanroeyMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Stephanie B HastingsMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Heidi KoMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Kyle C StricklandMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Rebecca A PrevisMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Shengle ZhangMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Jeffrey M ConroyMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Taylor J JensenMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Elizabeth GeorgeLabcorp, 531 South Spring Street, Burlington, NC 27215, United States.
Marcia EisenbergLabcorp, 531 South Spring Street, Burlington, NC 27215, United States.
Brian CaveneyLabcorp, 531 South Spring Street, Burlington, NC 27215, United States.
Pratheesh SathyanOncology Medical Affairs, Illumina Inc, 5200 Illumina Way, San Diego, CA 92122, United States.
Shakti RamkissoonMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.
Eric A SeversonMedical Oncology, Labcorp Oncology, 6 Moore Dr., Durham, NC 27560, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disparities in cancer diagnosis, treatment, and outcomes based on self-identified race and ethnicity (SIRE) are well documented, yet these variables have historically been excluded from clinical research. Without SIRE, genetic ancestry can be inferred using single-nucleotide polymorphisms (SNPs) detected from tumor DNA using comprehensive genomic profiling (CGP). However, factors inherent to CGP of tumor DNA increase the difficulty of identifying ancestry-informative SNPs, and current workflows for inferring genetic ancestry from CGP need improvements in key areas of the ancestry inference process. This study used genomic data from 4274 diverse reference subjects and CGP data from 491 patients with solid tumors and SIRE to develop and validate a workflow to obtain accurate genetically inferred ancestry (GIA) from CGP sequencing results. We use consensus-based classification to derive confident ancestral inferences from an expanded reference dataset covering eight world populations (African, Admixed American, Central Asian/Siberian, European, East Asian, Middle Eastern, Oceania, South Asian). Our GIA calls were highly concordant with SIRE (95%) and aligned well with reference populations of inferred ancestries. Further, our workflow could expand on SIRE by (i) detecting the ancestry of patients that usually lack appropriate racial categories, (ii) determining what patients have mixed ancestry, and (iii) resolving ancestries of patients in heterogeneous racial categories and who had missing SIRE. Accurate GIA provides needed information to enable ancestry-aware biomarker research, ensure the inclusion of underrepresented groups in clinical research, and increase the diverse representation of patient populations eligible for precision medicine therapies and trials.

Indexed as

GenomicsNeoplasmsPolymorphism, Single NucleotideWorkflowConsensusHumansPractice Guidelines as Topicancestrycancergenomic profilingmachine learningPCAsolid tumors

Identifiers

PMID39471413
PMCPMC11521331

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.